The FDA records linked to this profile identify Allergan as the applicant on two PMA numbers, P050047 for Juvéderm dermal fillers and P020056 for Natrelle silicone gel-filled breast implants. Both original approvals date to 2006, and both have since been amended through supplements. The linked collection holds four records, all approved, and the record sample used for dated examples also shows four approvals. Those counts describe the linked filings only, not company-wide activity. [1][2][3][4]
Dermal filler filings under P050047
P050047 was approved on June 2, 2006 for Juvéderm 24HV, Juvéderm 30 and Juvéderm 30HV gel implants, with an approval statement describing injection into the mid to deep dermis for correction of moderate to severe facial wrinkles and folds such as nasolabial folds. A later summary of safety and effectiveness data for P050047/S044, dated September 30, 2015, names Juvéderm Ultra XC as an injectable dermal filler under the same PMA number. [4][6]
The most recent linked record is P050047/S106, approved November 4, 2026, covering Juvéderm Ultra XC and Juvéderm Ultra Plus XC. Its approval statement addresses use of an additional supplier of high molecular weight sodium hyaluronate as a raw material in the manufacture of Juvéderm formulations. The supplement was received September 4, 2025 under the Normal 180 Day Track, with a change in design, components, specifications or material as the stated reason. [1]
Manufacturer documentation for Juvéderm Ultra Plus XC lists a composition of hyaluronic acid gel at 24 mg, lidocaine hydrochloride at 3 mg and phosphate buffer at pH 7.2 per 1 mL, with one syringe containing 1 mL. That document is published by Allergan and carries a 2022-06-30 revision date. [8]
Breast implant filings under P020056
P020056 was approved November 17, 2006 for Natrelle silicone-filled breast implants, with an approval statement describing breast augmentation and breast reconstruction indications. The record lists the device as a noninflatable internal silicone gel-filled breast prosthesis in class 3 under regulation number 878.3540, reviewed by the General and Plastic Surgery advisory committee. [3]
Supplement P020056/S064, approved September 29, 2026, covers Natrelle Silicone-Filled Breast Implants and Natrelle INSPIRA Silicone-Filled Breast Implants. The approval statement describes revised labeling to include results of the BIFS Arm study. The supplement was received September 12, 2024 under the Normal 180 Day Track No User Fee, with labeling change under a post-approval study as the stated reason. [2]
Applicant identity and record scope
The FDA records list Allergan at 2525 Dupont Drive, Irvine, California, for both PMA numbers. That address appears in filing data and is not treated here as a verified headquarters. The records name Allergan as applicant; no parent company, brand owner or corporate relationship is confirmed by these documents. [1][2][3][4]
The linked collection contains four PMA records, each with an approval decision, and no linked recall records appear in the same snapshot. The dated examples above come from the four-record sample, which likewise shows four approvals. Neither figure measures total company sales, total portfolio breadth or safety performance. [1][2][3][4]



